专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20210128615A1 METHODS AND COMPOUNDS FOR IMPROVED IMMUNE CELL THERAPY 有权
公开(公告)号：US20210128615A1
公开(公告)日：2021-05-06
申请号：US16757198
申请日：2018-10-18
申请人： Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus
发明人： Winfried Wels , Anja Waldmann , Congcong Zhang , Manuel Kaulich
IPC分类号： A61K35/17 , C12N5/0783 , C07K16/24 , C12N15/113 , C12N15/11
摘要： The present invention pertains to methods and compounds useful in a therapy involving the administration of immune cells to a patient. The method of the invention involves the modification of cells of the immune system with agonists or antagonists of immune regulators such as Interleukin-10 (IL-10) or IL-6, in order to enhance and improve the immunological potential of the immune cells for therapy. Cells modified according to the method of the invention can be administered to a patient to support a treatment of proliferative diseases such as cancer or autoimmune disorders.

2. 发明申请

WO2019077037A1 METHODS AND COMPOUNDS FOR IMPROVED IMMUNE CELL THERAPY 审中-公开
公开(公告)号：WO2019077037A1
公开(公告)日：2019-04-25
申请号：PCT/EP2018/078539
申请日：2018-10-18
申请人： CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS
发明人： WELS, Winfried , WALDMANN, Anja , ZHANG, Congcong , KAULICH, Manuel
IPC分类号： A61K35/17 , A61K39/00
摘要： The present invention pertains to methods and compounds useful in a therapy involving the administration of immune cells to a patient. The method of the invention involves the modification of cells of the immune system with agonists or antagonists of immune regulators such as Interleukin-10 (IL-10) or IL-6, in order to enhance and improve the immunological potential of the immune cells for therapy. Cells modified according to the method of the invention can be administered to a patient to support a treatment of proliferative diseases such as cancer or autoimmune disorders.

3. 发明申请

WO2015193411A1 CAR-EXPRESSING NK-92 CELLS AS CELL THERAPEUTIC AGENTS 审中-公开
公开(公告)号：WO2015193411A1
公开(公告)日：2015-12-23
申请号：PCT/EP2015/063674
申请日：2015-06-18
申请人： CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS , DRK BLUTSPENDEDIENST BADEN-WÜRTTEMBERG-HESSEN GGMBH
发明人： WELS, Winfried , SCHÖNFELD, Kurt , TONN, Torsten , GREZ, Manuel
IPC分类号： C07K16/32 , C12N5/0783
CPC分类号： C07K16/32 , A61K35/17 , A61K2039/505 , C07K14/7051 , C07K14/70521 , C07K16/2863 , C07K2317/622 , C07K2317/73 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/30 , C07K2319/33 , C07K2319/70 , C12N5/0646 , C12N15/86 , C12N2502/99 , C12N2740/16043
摘要： The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2- specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.
摘要翻译：本发明涉及含有编码嵌合抗原受体的慢病毒载体的ErbB2特异性NK-92细胞或细胞系，优选其细胞基因组中含有两个载体整合基因座。本发明还涉及ErbB2特异性NK-92细胞或细胞系在预防和/或治疗癌症，优选ErbB2表达癌症中的用途。本发明还涉及ErbB2特异性NK-92细胞或细胞系作为靶细胞治疗剂和/或用于过继性癌症免疫治疗的用途。本发明还涉及用于产生ErbB2特异性NK-92细胞或细胞系的方法以及用于鉴定ErbB2特异性NK-92细胞或细胞系和ErbB2特异性NK-92细胞的方法或通过方法获得或鉴定的细胞系及其用途。

4. 发明申请

WO2009087110A8 SECRETABLE HIV ENTRY INHIBITORY PEPTIDES FOR THERAPY OF HIV INFECTION 审中-公开
标题翻译：艾滋病毒感染治疗艾滋病毒入侵抑制肽的秘密性
公开(公告)号：WO2009087110A8
公开(公告)日：2010-08-26
申请号：PCT/EP2009000092
申请日：2009-01-09
申请人： VISION 7 GMBH , CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG SPEYER HAUS , LAER DOROTHEE VON , EGERER LISA
发明人： LAER DOROTHEE VON , EGERER LISA
IPC分类号： C07K14/16 , A61K48/00 , A61P31/18 , C12N15/867
CPC分类号： A61K48/005 , A61K38/00 , C07K14/005 , C12N15/86 , C12N2740/16043 , C12N2740/16222
摘要： The invention relates to gene therapy of HIV infection by providing to a patient a nucleic acid for the expression of in vivo secretable peptides that prevent entry of the virus into the cell. The invention makes available nucleic acids and vectors containing the same that code for a fusion protein which contains two HIV entry inhibitory peptides which are connected by a cleavable linker, wherein the peptides are preferably derived from the second (C) heptad repeat of the gp41 protein of HIV.
摘要翻译：本发明涉及通过向患者提供用于表达体内可分泌肽的核酸以防止病毒进入细胞的HIV感染的基因治疗。本发明提供含有与编码融合蛋白相同的核酸和载体，其含有通过可切割连接子连接的两个HIV进入抑制肽，其中肽优选衍生自gp41蛋白质的第二（C）七重复重复的艾滋病毒。

5. 发明申请

WO2008000445A1 EXPRESSION VECTOR(S) FOR ENHANCED EXPRESSION OF A PROTEIN OF INTEREST IN EUKARYOTIC OR PROKARYOTIC HOST CELLS 审中-公开
标题翻译：表达载体（S）用于增强在原核细胞或原核细胞中的兴趣蛋白质的表达
公开(公告)号：WO2008000445A1
公开(公告)日：2008-01-03
申请号：PCT/EP2007/005650
申请日：2007-06-26
申请人： CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS , WELS, Winfried , DÄLKEN, Benjamin
发明人： WELS, Winfried , DÄLKEN, Benjamin
IPC分类号： C12N15/70 , C12N15/79
CPC分类号： C12N15/81 , C12N15/625
摘要： The present invention refers to an expression vector (A) for enhanced expression of a protein of interest encoding a fusion protein comprising at least a secretory signal sequence (A1); a solubilizing agent (A2); a proteolytic cleavage site (A3); and a protein of interest (A4), optionally a tag for purification of the protein of interest (A5) and optionally a heterologously expressed protease (A6), capable of cleaving the proteolytic cleavage site (A3) subsequent to or during secretion of the fusion protein. Alternatively, the protease (A6) may be endogenously expressed in the host cell, may be provided to the host cell using a second expression vector (B) and/or may be added extracellularly. The present invention furthermore provides methods for using the inventive expression vectors (A) and, optionally, (B), in vitro and in vivo , and kits, comprising these expression vectors and/or cells comprising same.
摘要翻译：本发明涉及用于增强编码融合蛋白的目的蛋白质表达的表达载体（A），其至少包含分泌信号序列（A1）; 增溶剂（A2）; 蛋白水解切割位点（A3）; 和感兴趣的蛋白质（A4），任选地用于纯化目的蛋白质的标签（A5）和任选的异源表达的蛋白酶（A6），其能够在融合分泌之后或期间切割蛋白水解切割位点（A3）蛋白。或者，蛋白酶（A6）可以在宿主细胞中内生表达，可以使用第二表达载体（B）提供给宿主细胞和/或可以在细胞外加入。本发明还提供了在体外和体内使用本发明的表达载体（A）和任选的（B）的方法，以及包含这些表达载体和/或包含它们的细胞的试剂盒。

6. 发明授权

US12023353B2 Methods and compounds for improved immune cell therapy 有权
公开(公告)号：US12023353B2
公开(公告)日：2024-07-02
申请号：US16757198
申请日：2018-10-18
申请人： Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus
发明人： Winfried Wels , Anja Waldmann , Congcong Zhang , Manuel Kaulich
IPC分类号： A61K35/17 , C07K16/24 , C12N5/0783 , C12N15/11 , C12N15/113
CPC分类号： A61K35/17 , C07K16/244 , C07K16/248 , C12N5/0646 , C12N15/11 , C12N15/1136 , C07K2317/76 , C12N2310/14 , C12N2310/20 , C12N2501/2312 , C12N2501/2315
摘要： The present invention pertains to methods and compounds useful in a therapy involving the administration of immune cells to a patient. The method of the invention involves the modification of cells of the immune system with agonists or antagonists of immune regulators such as Interleukin-10 (IL-10) or IL-6, in order to enhance and improve the immunological potential of the immune cells for therapy. Cells modified according to the method of the invention can be administered to a patient to support a treatment of proliferative diseases such as cancer or autoimmune disorders.

7. 发明公开

US20230365673A1 MEANS FOR REDUCING RADIO- AND CHEMOTHERAPY RESISTANCE AND ADVERSE EFFECTS 审中-公开
公开(公告)号：US20230365673A1
公开(公告)日：2023-11-16
申请号：US18245529
申请日：2021-09-15
申请人： JOHANN WOLFGANG GOETHE-UNIVERSITÄT FRANKFURT AM MAIN , CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS
发明人： Florian GRETEN , Adele NICOLAS , Claus RÖDEL , Emmanouil FOKAS
IPC分类号： C07K16/24 , G01N33/50 , C07K16/28 , C07K14/715 , A61K45/06 , A61P35/00
CPC分类号： C07K16/245 , G01N33/5044 , C07K16/2866 , C07K14/7155 , A61K45/06 , A61P35/00 , A61N2005/1098
摘要： The invention is based on the modulation of cancer-associated fibroblasts (CAFs) in the treatment of proliferative disorders by radiotherapy. By reducing CAF sensitivity to cellular senescence adverse immune reactions upon radiotherapy of solid tumours and subsequent treatment resistance could be avoided. The invention pertains to senolytics or Interleukin 1 (IL1) signalling inhibitors for use in a method of treating solid tumours and in the treatment or prevention of inflammatory adverse effects upon radiation therapy in context of a cancer treatment. The invention optionally also pertains to senolytics or Interleukin 1 (IL1) signalling inhibitors for use in a method of treating solid tumours and in the treatment or prevention of inflammatory adverse effects upon chemotherapy and/or radiation therapy in context of a cancer treatment.

8. 发明授权

US09920132B2 Car-expressing NK-92 cells as cell therapeutic agents 有权
公开(公告)号：US09920132B2
公开(公告)日：2018-03-20
申请号：US15599601
申请日：2017-05-19
申请人： CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS , DRK BLUTSPENDEDIENST BADEN-WURTTEMBERG-HESSEN GGMBH
发明人： Winfried Wels , Kurt Schonfeld , Torsten Tonn , Manuel Grez , Congcong Zhang
IPC分类号： C07K16/32 , C07K16/28 , C07K14/00 , C07K14/705 , C07K14/725 , A61K39/00
CPC分类号： C07K16/32 , A61K35/17 , A61K2039/505 , C07K14/7051 , C07K14/70521 , C07K16/2863 , C07K2317/622 , C07K2317/73 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/30 , C07K2319/33 , C07K2319/70 , C12N5/0646 , C12N15/86 , C12N2502/99 , C12N2740/16043
摘要： The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.

9. 发明授权

US08530637B2 Optimized DNA sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins 有权
标题翻译：优化抗体的DNA序列，以提高细菌表达的抗体融合蛋白的质量和产量
公开(公告)号：US08530637B2
公开(公告)日：2013-09-10
申请号：US12985542
申请日：2011-01-06
申请人： Winfried S. Wels , Benjamin Daelken , Sylvia E. Schwarz
发明人： Winfried S. Wels , Benjamin Daelken , Sylvia E. Schwarz
IPC分类号： C07H21/04
CPC分类号： C07K16/32 , A61K31/7088 , C07K14/21 , C07K2317/622 , C07K2319/00 , C07K2319/55
摘要： Object matter of the invention is an optimized DNA sequence encoding the scFv(FRP5) antibody fragment. This novel sequence prevents the generation of the undesired by-product in the context of an scFv(FRP5)-ETA fusion protein, and possibly also other bacterially expressed scFv(FRP5)-containing fusion proteins. The DNA sequence of the scFv(FRP5) domain of scFv(FRP5)-ETA was modified by exchanging a distinct codon, thereby preventing an otherwise possible internal start of protein translation.
摘要翻译：本发明的目的是编码scFv（FRP5）抗体片段的优化的DNA序列。该新型序列防止在scFv（FRP5）-ETA融合蛋白以及可能还有其它细菌表达的scFv（FRP5）融合蛋白的上下文中产生不需要的副产物。通过交换不同的密码子修饰scFv（FRP5）-ETA的scFv（FRP5）结构域的DNA序列，从而防止蛋白质翻译的另外可能的内部启动。

10. 发明申请

WO2021239817A1 THERAPEUTIC COMBINATIONS COMPRISING AGONISTS OF FERROPTOSIS FOR TREATING PROLIFERATIVE DISORDERS 审中-公开
公开(公告)号：WO2021239817A1
公开(公告)日：2021-12-02
申请号：PCT/EP2021/064064
申请日：2021-05-26
申请人： CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS , JOHANN WOLFGANG GOETHE-UNIVERSITÄT FRANKFURT AM MAIN
发明人： GRETEN, Florian , CONCHE, Claire , FINKELMEIER, Fabian , NICOLAS, Adele
IPC分类号： A61K45/06 , A61K31/585 , A61K39/395
摘要： The invention is based on the finding that ferroptosis mediated cell death results in the local recruitment of immune cells and that a concomitant sensitization of tumour tissue and tumour cells to a cell-mediated immune response results in synergistic therapeutic effects against proliferative diseases. By inducing or supporting ferroptosis, such as inhibition of its key regulators, it could be shown that tumour cells become sensitized to immune checkpoint inhibition, which was even further improved when also myeloid cell recruitment is blocked. Hence, the enhanced recruitment of immune cells via ferroptosis can be harnessed for anti- tumour response by immune checkpoint inhibition and/or suppression of local recruitment of immune suppressive cell fractions. The invention provides such combinatorial approaches to treat proliferative disorders, preferably solid cancers which are characterized by a resistance to immune checkpoint inhibition, which often is observed in hepatocellular carcinoma. The invention pertains to the medical application of ferroptosis induction using ferroptosis agonists in combination with immune checkpoint inhibition – such as inhibition of the PD-1/PD-L1 axis – in the treatment and prevention of proliferative disorders. The invention provides compounds and compositions for use in the indicated medical approaches.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式